2009). EZH2 is also the target of miR‐101, and the genomic loss of miR‐101 in cancer leads to overexpression of EZH2, resulting in cancer progression (Cao et al. 2010; Varambally et al. 2008). However, the role of EZH2 in IPF is unknown. One study has shown a role of EZH2‐mediated hypermethylation in the epigenetic silencing of cyclooxygenase 2 (COX‐2), which reduces the production of the antifibrotic protein prostaglandin E2 (Cao et al. 2010). The gene discussed is PTGS2; the disease is idiopathic pulmonary fibrosis.